{
  "ticker": "NTI",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958560",
  "id": "02958560",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250616",
  "time": "0859",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06kryy4sl84vd0.pdf",
  "summary": "- **Appointment of Chief Medical Advisor USA**: Dr. Bonni Goldstein, a renowned expert in paediatric cannabinoid medicine, joins to support regulatory strategy, clinical advancement, and US market visibility for NTI164.  \n- **Strategic Impact**: Strengthens Neurotech's credibility and clinical capability for its cannabinoid-based therapy (NTI164) targeting paediatric neurological disorders (e.g., autism, epilepsy, Rett syndrome).  \n- **Market Validation**: High-profile appointment signals confidence in NTI164's potential and aligns with commercialization efforts (pending regulatory approval).  \n\nNo material financial or capital markets data disclosed.",
  "usage": {
    "prompt_tokens": 1454,
    "completion_tokens": 123,
    "total_tokens": 1577,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T23:14:46.252998"
}